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Abstract: SiO2-CaO-P2O5 ternary bioactive glass ceramic
(BGC) nanoparticles with different compositions were
prepared via a three-step sol-gel method. Polyethylene
glycol was selected to be used as the surfactant to
improve the dispersion of the nanoparticles. The mor-
phology and composition of these BGC nanoparticles
were observed by ESEM and EDX. All the BGC particles
obtained in this method were about 20 nm in diameter.
XRD analysis demonstrated that the different composi-
tions can result in very different crystallinities for the
BGC nanoparticles. Bioactivity tests in simulated body
fluid solution (SBF), and degradability in phosphate
buffer solution (PBS), were performed in vitro. SEM, EDX,
and XRD were employed to monitor the surface variation
of neat poly(L-lactic acid), PLLA, foam and PLLA/BGC
porous scaffolds during incubation. The BGC nanopar-
ticles with lower phosphorous and relative higher silicon
content exhibited enhanced mineralization capability in
SBF and a higher solubility in PBS medium. Such novel
nanoparticles may have potential to be used in different
biomedical applications, including tissue engineering or
the orthopedic field. ! 2008 Wiley Periodicals, Inc. J
Biomed Mater Res 88A: 304–313, 2009
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INTRODUCTION
Since Hench et al.1 developed the Bioglass1,
increasing attention has been paid to bioactive
glasses and glass-ceramic systems for their excellent
biocompatibility and bioactivity in bone tissue engi-
neering. It has been found that silicon component
plays the key role in bone mineralization instead of
calcium. When implanted, bioactive glass can release
soluble silicon via interfacial reaction with body
fluid and induces the formation of calcium deficient
hydroxyapatite (HAP) layer on the surface of bioac-
tive glass. This biologically active HAP layer is
chemically similar with the mineral phase of natural
bone, allowing bioactive glass to chemically bond to
surrounding tissue. So, the formation of HAP is the
critical stage for the bonding of bioactive glasses to
regenerated bone and to promote the contact
between the implant and the host bone tissue.2
In vivo studies showed that bioactive glass system
has remarkable advantage for regeneration of bone
tissue compared to HAP ceramic.3 It is generally
accepted that bioactive glass is a more promising
biomaterial than HAP in bone tissue engineering.4–6
Numerous reports about preparation of bioactive
glass materials have been published in past decades,
including bulk bioactive glass,7–10 bioactive glass
particles, and their composites.11–22 The structure
and composition of the glasses can be tailored by
controlling the fabrication parameter.23,24 Different
types of bioactive glasses were designed for different
utilization in bone tissue engineering. Porous bioac-
tive glass can be obtained by sol–gel methods based
on the use of granular polyethylene glycol (PEG) as
pore former. Its porous structure, with coexistent
macro and mesopores, was suitable for tissues and
blood vessel ingrowths, and presented simultane-
ously the capability of forming a HAP surface layer.7
Such advantages make these bioactive glass promis-
ing materials to be used in bone tissue engineering
and bone regeneration.
However, compared with natural bone tissue, bio-
active glasses, especially when processed as foams,
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exhibit lower mechanical properties. In particular,
the low fracture toughness limits the application of
bioactive glasses as scaffold structures in load-bear-
ing situations. General values of mechanical proper-
ties for bulk bioactive glass materials were summar-
ized by Rezwan et al.25
The development of biopolymer/bioactive glass
and biopolymer/bioactive ceramic composites has
been recognized as a strategy to improve the me-
chanical behavior of bioactive glass-based materi-
als.11–14 Composites combining bioactive glass par-
ticles and biopolymers have become very promising
systems for bone reconstruction or regeneration by
combining the advantages of each component in one
material.15–22 Compared with microsized bioactive
ceramic particles, nanosized particles have a large
surface area and can form a more tight interface
with polymer matrix in composites, and hence, a
high performance in mechanical properties can be
expected.26–29 In this context, most of the studies
have been reporting systems based on HAP nano-
particles and the works based on bioactive glasses
are scarce.30–33 In this work, bioactive glass ceramic
(BGC) nanoparticles with different compositions
were prepared by means of a three-step sol–gel
method, and the physical, chemical, and bioactive
properties of these nanoparticles were characterized.
To check the bioactive character in potential tissue
engineering applications, model scaffolds were pre-
pared by combining poly(L-lactic acid), and the pro-
duced glass ceramic nanoparticles.
MATERIALS AND METHODS
Materials
Tetraethoxysilane (TEOS), calcium nitrate, citric acid,
and ammonium dibasic phosphate were obtained from
Sigma. PEG (Mn: 16,000–24,000) and Dioxane were pur-
chased from Fluka. Poly(L-lactic acid) (PLLA, Mw: 200,000)
was obtained from Stratec.
Preparation of BGC nanoparticles based
on SiO2-CaO-P2O5
The procedure for preparing the BGC-55 nanoparticles
(SiO2:CaO:P2O5 (mol) 5 55:40:5) was based on the method
reported elsewhere34 and was described as follows: (1) In
an well-washed beaker equipped with a magnetic stirrer,
7.639 g calcium nitrate was dissolved in 120 mL of deion-
ized water at room temperature. The TEOS-ethanol solution
was created by diluting 9.167 g of TEOS in 60 mL of ethanol
and added to the calcium nitrate solution. Then, citric acid
was added into the solution to adjust the pH value to 1–2.
The reaction mixture was kept stirring until a homogeneous
and transparent solution was obtained. (2) Under vigorous
stirring, the homogenous solution was slowly dropped into
1500 mL of ammoniated deionized water, in which 1.078 g
of ammonium dibasic phosphate was dissolved in advance.
During the dripping process the pH value of solution was
kept at around 11 using ammonia water. (3) After stirred 48
h and aged for 24 h, the precipitate was separated from the
reaction solution by centrifugation at 1000 rpm, washed
three times with deionized water, and finally separated in
200 mL of 2% PEG-water solution and kept still. (4) The pre-
cipitation was freeze dried and followed by calcination at
7008C in a muffle furnace for 3 h, after which the white
BGC nanoparticles were obtained. BGC-30 (SiO2 : CaO :
P2O5 (mol) 5 30 : 60 : 10) and BGC-68 (SiO2 : CaO : P2O5
(mol) 5 68 : 28 : 4) were also obtained in this route by varia-
tion of reactant quantity.
Preparation of PLLA/BGC
nanocomposite scaffold
Preparation of PLLA/BGC composite porous scaffolds
was based on thermal induced phase separation that was
similar with the process described elsewhere.35 Briefly, a
given amount of BGC powder was homogeneously sus-
pended in dioxane with ultrasonication and magnetic stir.
PLLA was dissolved in a BGC-dioxane suspension to pro-
duce a polymer weight to solvent volume ratio of 5%. The
mixture was stirred overnight to obtain a homogeneous
polymer solution. After lyophilization at 2808C for 1 week,
porous PLLA/BGC composite scaffolds were obtained.
Field emission scanning electron microscopy
The morphology of the BGC nanoparticles was observed
using field emission scanning electron microscopy (ESEM)
(XL30 ESEM FEG; Philips) equipped with energy-disper-
sive X-ray spectroscopy (EDX).
Fourier-transformed infrared
spectroscopy analysis
A Bio-Rad Win-IR spectrometer was employed for the
Fourier-transformed infrared (FTIR) spectroscopy analysis.
The samples of BGC powders were mixed with KBr powder
and pressed into a disk suitable for FTIR measurement. The
FTIR spectra were recorded from 4000 cm21 to 400 cm21.
X-ray diffraction
X-ray diffraction (XRD) analysis were performed on an
X-ray diffractometer (Philips PW 1710, Netherlands) with a
Cu Ka radiation (k 5 0.154 nm). Voltage and current were
selected at 40 kV and 50 mA, respectively. Data were col-
lected from 2u 5 108 to 608 with a step size of 0.028.
In vitro bioactivity study
In vitro bioactivity test were carried out by soaking the
10 3 10 3 2 mm3 porous scaffolds in 10 mL of simulated
body fluid (SBF) (Naþ 142.0, Kþ 5.0, Ca2þ 2.5, Mg2þ 1.5, Cl2
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148.0, HCO32 4.2, HPO4
22 1.0, SO4
22 0.5 mM) in conical
flasks, and placed in an oven at 378C for periods of 1, 3, 7,
14, and 21 days. To terminate the reactions after the different
soaking periods, the scaffolds were taken out from SBF,
rinsed with deionized water, and freeze dried for 1 week.
The formation of apatite onto the porous PLLA and PLLA/
BGC composite were characterized by SEM, EDX, and XRD.
For SEM observation, samples were coated with gold. For
EDX analysis, all samples were coated with carbon to avoid
the overlap of the peaks of gold and phosphorous.14,36
SEM and EDX analysis
The morphologies of the PLLA and PLLA/BGC compo-
sites after soaking in SBF for different periods were
observed using SEM (Leica Cambridge S 360 microscope).
For SEM observation, samples were coated with gold. For
EDX analysis, all samples were coated with carbon to
avoid the overlap of the peaks of gold and phosphorous.
In vitro degradation study
For degradation experiments, samples of neat polymer
and composite scaffolds were cut into small pieces with
dimensions of 10 3 10 3 2 mm3. The samples were steri-
lized by UV exposure under a laminar flow hood for
10 min on each side and placed in sterile Falcon tube. For
each time point, three samples of each scaffold composi-
tion were immersed in 10 mL of phosphate-buffered sa-
line. The phosphate buffer solution (PBS) was prepared by
dissolving one tablet of PBS, from Sigma-Aldrich, in 200
mL of distilled water to obtain a final concentration of
0.227M potassium chloride and 0.137M sodium chloride, at
pH 5 7.4. The samples were incubated under slow tangen-
tial agitation at 378C. The pH of the buffer was monitored
Figure 1. ESEM micrographs and EDX curves for BGC nanoparticles with different compositions. (a) BGC-30, (b) BGC-
55, and (c) BGC-68. Bar is 200 nm.
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during the experiment. At different time points, samples
of each scaffold composition were removed from the PBS
and weighted (Ww) after surface wiping with filter paper.
Each sample was drastically rinsed with deionized water
to remove the soluble inorganic salt, and weighed (Wd)
after completely dried in oven. The pH of the medium
was recorded at each time point. Water absorption (WA%)
and weight loss (WL%) were calculated according to Eqs. (1)
and (2), respectively:
WA% ¼ Ww #Wið Þ=Wi½ ' 3 100% ð1Þ
WL% ¼ Wd #Wið Þ=Wi½ ' 3 100% ð2Þ
whereWi was the initial weight of each sample.
RESULTS AND DISCUSSION
BGC nanoparticles
ESEM micrographs and EDX curves of BGC par-
ticles with different compositions are shown in Fig-
ure 1. Most of BGC particles exhibit a spherical form
with about 20 nm in diameter. No obvious difference
both in size and morphology could be seen between
the three sets of samples. EDX curves showed the
different concentrations of Si, P, and Ca, which well
agreed with the different compositions of three types
of the BGC nanoparticles studied.
The FTIR spectra of the BGC nanoparticles with
different compositions were presented in Figure 2.
Two peaks at 1043 and 1091 [Fig. 2(a)] arose from
P##O bond were shifted to a broad and strong
absorption band at 1100 cm21 [Fig. 2(b,c)] that could
be ascribed to the stretch vibration of Si##O##Si
bond. Small band at 810 cm21 was the absorption
band of symmetric stretch vibration of Si##O bond.
Two sharp bands could also be noted at 603 cm21
and 568 cm21 in Figure 1(a), which should be attrib-
uted to the bending vibration of P##O bond in crys-
tal phosphate. These twin bands merged into a weak
dispersive band at 570 cm21 in Figure 1(a), which
arose from the bending vibration of amorphous
P##O bond.
Figure 3 showed the XRD spectra of the BGC
powders with the different compositions. The spec-
tra of BGC-55 and BGC-68 were a broad dispersive
band as shown in Figure 3(b,c), indicating the amor-
phous nature of the two materials. BGC-30 was crys-
talline, showing sharp phosphate crystal peaks
appeared at 2u 5 328 and 2u 5 268 [see Fig. 3(a)].
Such results shows that the crystallinity of BGC par-
ticles obtained at the same preparation condition
could increase with increasing phosphate content,
being in agreement with the FTIR results.
In vitro bioactivity tests
The morphology of the porous scaffolds of PLLA
and the composite of PLLA/25% BGC-30 was shown
in Figure 4. SEM images of neat PLLA foam [Fig.
4(a,b)] showed a continuous microstructure of nearly
interconnected pores with dimensions between 10
and 300 lm diameter. The morphology of PLLA/
BGC foam did not show too much difference from
the image of the PLLA scaffold. This was an indica-
tion that the BGC particles did not remarkably
change the mechanism of pore formation by crystal-
lization of dioxane solvent at 25 wt % of BGC load.
In the high magnification image of PLLA/BGC com-
posite [Fig. 4(d)], some microsized BGC clusters
could be seen on the wall of microporous structure,
Figure 2. FTIR spectra of BGC nanoparticles with differ-
ent compositions. (a) BGC-30, (b) BGC-55, and (c) BGC-68.
[Color figure can be viewed in the online issue, which is
available at www.interscience.wiley.com.]
Figure 3. XRD patterns for the BGC nanoparticles with
different compositions. (a) BGC-30, (b) BGC-55, and (c)
BGC-68. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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which revealed that BGC particles can, to some
extent, agglomerate in the PLLA matrix at 25 wt %
of BGC content.
Figure 5 shows the morphology of porous PLLA
and PLLA/BGC composites scaffolds after soaking
in SBF for different periods. Different types of BGC
particles exhibit very different bioactive performance
in SBF. After 1 day of immersion in SBF, the cauli-
flower-like apatite cluster formed on the surface of
PLLA/BGC-55 and PLLA/BGC-68 composites as
shown in Figure 5(c1,d1), and grew with increasing
immersion time as shown in Figure 5(c3,d3). After 14
days of incubation, most of the PLLA/BGC-55 and
PLLA/BGC-68 scaffold surfaces were covered by
needle-like apatite layer as shown in Figure
5(c14,d14). The apatite layers were further thickened
in the SEM images after 21 days of incubation period
[Fig. 5(c21,d21)]. Oppositely, no apatite formation was
detected in the SEM images for both neat PLLA and
PLLA/BGC-30 composite after soaking in SBF for
different times [see Fig. 5(a,b)].
The results obtained by SEM were confirmed by
EDX analysis (see Fig. 6). No notorious changes
could be detected in the EDX curves for PLLA and
PLLA/BGC-30 composite before and after soaking in
SBF [Fig. 6(a,b)], whereas a significant variation in
the intensity of Si, P, and Ca can be observed on Fig-
ure 6(c,d). It could be noticed that after soaking in
SBF, the concentrations of Ca and P gradually and
significantly increased accompanied by the decreas-
ing of concentration of Si, in comparison with the
initial materials, which strengthens the indication of
a development of apatite material onto the surfaces
of PLLA/BGC-55 and PLLA/BGC-68.14,37 FTIR anal-
ysis has proved that this apatite formed by induce-
ment of BGC nanoparticles in SBF was carbonated
hydroxyapatite particles.34
To characterize the inorganic phase formed onto
the surfaces of PLLA/BGC-55 and PLLA/BGC-68
scaffolds, XRD analysis was performed on the differ-
ent materials. Figure 7 shows XRD patterns of the
PLLA and the different PLLA/BGC nanocomposites
after soaking in SBF for 14 days. As observed in Fig-
ure 7(a), porous PLLA scaffold displays a typical
amorphous behavior, which indicated that the crys-
tallization of PLLA could be prevented by the proc-
essing technique utilized. In Figure 7(c,d), the typical
crystalline diffraction pattern of apatite can be
observed with an evident peak at 2u 5 31.78, which
confirms that partially crystallized apatite layer
formed on the surfaces of PLLA/BGC-55 and PLLA/
BGC-68. For PLLA/BGC-30 composite [Fig. 7(b)], an
obvious peak appeared near 2u 5 32.48. However, it
was not clear of the origin of the peaks because there
was overlapping between the peaks of the BGC-30
nanoparticles and apatite that may form on the sur-
face of PLLA/BG-30 composite after soaking in SBF.
In summary, BGC-55 and BGC-68 exhibit more pro-
nounced bioactivity behavior, as tested in vitro using
SBF, than BGC-30. This finding was in agreement
Figure 4. SEM micrographs for the PLLA scaffold at (a) low magnification and (b) high magnification. The morphology
of the PLLA/BGC-30 composite scaffold is also shown at (c) low magnification and (d) high magnification.
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with previous report that crystallization of bioactive
glasses decreases the level of bioactivity and even
turns a bioactive glass into bioinert material. The for-
mation of a crystalline apatite layer on the surface of
BGC materials was a very complicated process. Sev-
eral steps of chemical and physical reaction such as
solubility of BGC material, ion exchange between
BGC and SBF solution, and hydroxylation of the
materials surface were involved in this biomimetic
process. The amorphous phase of BGC controlled the
rate of ion exchange and silanol formation; the less
crystallized BGC materials demonstrated higher bio-
activity in mineralization test in vitro.38,39
In vitro degradation of nanocomposite
of PLLA and BGC
To study the solubility of different types of BGC
and their effect on the degradation behavior of
PLLA matrix, the in vitro degradation profile of
PLLA and composite samples were determined as a
function of the incubation time in PBS (pH 5 7.4) at
378C. The degradation of PLLA and PLLA/BGC
composites was monitored by water absorption,
weight loss, and pH variation in PBS medium.
Figure 8 showed the water absorption of neat
PLLA and PLLA/BGC composites foams. It was
observed that after 1 day of immersion in PBS, all
samples exhibit considerable water uptake values
due mostly to the filling of the pores with water.
There was a mass increase of 600% for pure PLLA
foam, whereas for all PLLA/BGC composites water
uptake was about 650%. Comparing with PLLA po-
rous scaffold, the water absorption rate should have
a remarkable increase for PLLA/BGC composite
with the introduction of hydrophilic BGC powder.35
However, no obvious increase in water absorption
rate could be seen between the PLLA and PLLA/
BGC composites, which should be due to the
Figure 5. SEM micrographs for the PLLA scaffold (a) and the different types of PLLA/BGC composites after incubation
in SBF for different periods: (b) BGC-30, (c) BGC-55, and (d) BGC-68. The subscripts indicate the different incubation times
in SBF (in days).
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Figure 6. EDX curves for the PLLA scaffold (a) and the different types of PLLA/BGC composites after incubation in SBF
for different periods: (b) BGC-30, (c) BGC-55, and (d) BGC-68. The subscripts indicate the different incubation times in
SBF (in days).
Figure 8. Water absorption versus incubation time in PBS
for the porous scaffold of PLLA and the different types of
PLLA/BGC composites. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.
com.]
Figure 7. XRD patterns for the PLLA scaffold (a) and the
different types of PLLA/BGC composites after incubation
in SBF for 14 days: (b) BGC-30, (c) BGC-55, and (d) BGC-
68. [Color figure can be viewed in the online issue, which
is available at www.interscience.wiley.com.]
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decrease of the porosity after introduction of inor-
ganic filler in the polymeric fraction.40 After 7 days
of incubation, water absorption reached a maximum
and stabilized at that value until 30 days of incuba-
tion time for all samples. No significant difference
could be seen in the trends among the three types of
PLLA/BGC composites.
The pH variation of the media containing different
types of PLLA/BGC composites was presented in
Figure 9. A burst decrease in pH value occurred at
early incubation time for PLLA and PLLA/BGC-30
composite. The pH value for PLLA and PLLA/BGC-
30 were always lower than the initial value during
the entire incubation time range. After 3 days of
incubation, the pH value of the medium for neat
PLLA foam reached a plateau value at around 7.3,
whereas the pH value for PLLA/BGC-30 continu-
ously decreased during the 30 days of incubation
time. For the case of both PLLA/BGC-55 and PLLA/
BGC-68 composites, the pH value of the incubation
medium slightly increases in the first day of incuba-
tion and then decreased gradually, stabilizing at
around 7.2 after 2 weeks of incubation time. Degra-
dation of PLLA releases a lot of acidic low molecular
weight products that could rapidly decrease the pH
value of incubation medium. Meanwhile, Ca and Si
ions dissolved from BGC particles can compensate
the decrease of pH value due to the acidic products
of PLLA degradation. This neutralization effect of
basic ions released from BGC particles could provide
a pH buffering effect on the material surface con-
tacted with PBS.11,41 Comparing with BGC-55 and
BGC-68, BGC-30 did not exhibit a notable compensa-
tion effect on the pH value of incubation medium,
which was very similar to the result of incorporation
of HAP particle into PLA matrix.41
The weight loss for the porous PLLA and PLLA/
BGC composite scaffolds were shown in Figure 10.
There was a rapid increase in weight loss for all
composites independently on the BGC composition
for early incubation times, followed by a more slow
variation of this quantity. Compared with composite
scaffolds, pure PLLA foam demonstrated a slow
weight loss rate. During the 30 days of incubation
period, the PLLA scaffold just lost about 2 wt % of
its initial mass; such mass loss was consistent with
the typical degradation profile of PLLA that may be
considered as a slow biodegradable polymer. The
weight loss for PLLA/BGC-30 composite was
slightly higher than the other two composites. After
30 days of incubation the PLLA/BGC-30 composites
could have lost about 6% of the initial mass, whereas
the weight loss for the PLLA/BGC-55 and PLLA/
BGC-68 were in range of 4–5%. Weight loss of com-
posites resulted from not only the degradation of
PLLA but also dissolution of BGC particles during
incubation in PBS. Degradation of PLLA first
occurred on the interface that was contacted with
PBS. Introduction of hydrophilic BGC particles could
absorb PBS into the inside of composite so that the
interface between PLLA matrix and PBS would be
increased. No doubt, it would accelerate the degra-
dation of PLLA matrix. Compared with BGC-55 and
BGC-68, BGC-30 showed a more accelerative effect
on the degradation of PLLA matrix. This should be
attributed to the low dissolubility of crystallized
BGC-30 particle in PBS. The in vitro degradation
results suggest that BGC-55 and BGC-68, when com-
pared with BGC-30, might delay the degradation of
the composite scaffolds by the neutralization effect
of alkaline ions that were released from the BGC
nanoparticles in the PBS medium. In a tissue engi-
Figure 9. Change in pH in PBS medium versus incuba-
tion time for the porous scaffold of PLLA and the different
types of PLLA/BGC composites. [Color figure can be
viewed in the online issue, which is available at www.
interscience.wiley.com.]
Figure 10. Weight loss versus incubation time in PBS for
the porous scaffold of PLLA and the different types of
PLLA/BGC composites. [Color figure can be viewed in the
online issue, which is available at www.interscience.wiley.
com.]
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neering context, this could have a beneficial effect at
a longer implantation time scale, avoiding the typical
consequences resulting from the decrease of pH due
to polymer hydrolysis.
CONCLUSIONS
Different formulations of BGC nanoparticles were
obtained by a three-step sol–gel method in the pres-
ence of PEG as surfactant. This method enabled to
obtain particles with sizes of around 20 nm. The
XRD patterns for the different types of BGC nano-
particles showed that for higher contents of phos-
phate the SiO2-P2O5-CaO glass ceramic system could
exhibit a crystalline structure upon calcification at
7008C. Hence, the BGC particles with lower phos-
phate content demonstrated higher solubility in PBS
medium when compared with BGC-30. The porous
scaffolds of PLLA/BGC composites were prepared
by a thermal induced phase separation method. The
microstructure of the PLLA/BGC composite foams
consisted of pores with 10–300 lm diameter sepa-
rated by 2–5 lm thick walls. In addition, the in vitro
tests indicated that BGC-55 and BGC-68 have better
bioactivity than BGC-30. These results suggest that
these novel BGC nanoparticles may find applications
in the development of new systems for bone tissue
engineering and bone tissue regeneration.
The authors acknowledge Dr. Aixue Liu for the ESEM,
XRD, and FTIR testing at Changchun Institute of Applied
Chemistry.
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